Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Caliber Imaging & Diagnostics's Equity-to-Asset or its related term are showing as below:
LCDX's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.65 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Caliber Imaging & Diagnostics Equity-to-Asset Related Terms
Caliber Imaging & Diagnostics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LCDX vs VICA, CRVW, RSLS: Equity-to-Asset Comparison
For the Medical Devices subindustry, Caliber Imaging & Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliber Imaging & Diagnostics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Caliber Imaging & Diagnostics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliber Imaging & Diagnostics (LCDX) has a Equity-to-Asset of -6.41 as of Mar. 2014. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' Equity-to-Asset too high?
Caliber Imaging & Diagnostics' current Equity-to-Asset is -6.41.
How does Caliber Imaging & Diagnostics' Equity-to-Asset compare to VICA and CRVW?
Caliber Imaging & Diagnostics' Equity-to-Asset of -6.41 can be compared against companies in the Medical Devices & Instruments industry. The industry median Equity-to-Asset is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Caliber Imaging & Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliber Imaging & Diagnostics's current Equity-to-Asset is -6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current Equity-to-Asset of -6.41. The current Equity-to-Asset is -6.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current Equity-to-Asset is -6.41 as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caliber Imaging & Diagnostics Business Description
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCDX has been successfully added to your 
